The role of c-FLIP splice variants in urothelial tumours

Cell Death and Disease

Volumn 2, Issue 12, 2011, Pages

  Ewald, F ^a   Ueffing, N ^b,c   Brockmann, L ^b   Hader, C ^b   Telieps, T ^a   Schuster, M ^a   Schulz, W A ^b   Schmitz, I ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

Apoptosis; Bladder cancer; Cancer therapy resistance; Death receptor

Indexed keywords

FAS LIGAND; FLICE INHIBITORY PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; CFLAR PROTEIN, HUMAN; CYCLOHEXIMIDE; ISOPROTEIN; MESSENGER RNA; SMALL INTERFERING RNA;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER TISSUE; CELL DEATH; CELL PROTECTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TRANSITIONAL CELL CARCINOMA; BLADDER TUMOR; DRUG EFFECT; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; RNA SPLICING; TUMOR CELL LINE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; CYCLOHEXIMIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN ISOFORMS; RNA INTERFERENCE; RNA SPLICING; RNA, MESSENGER; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; URINARY BLADDER NEOPLASMS;

EID: 84856094556     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2011.131     Document Type: Article

References (40)

1. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002; 2: 277-288. (Pubitemid 37328781)
2. Shirley S, Micheau O. Targeting c-FLIP in cancer. Cancer Lett 2010; e-pub ahead of print 9 November 2010; doi:10.1016/j.canlet.2010.10.009.
3. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999; 274: 1541-1548.
4. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-195. (Pubitemid 27297457)
5. Golks A, Brenner D, Fritsch C, Krammer PH, Lavrik IN. c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem 2005; 280: 14507-14513. (Pubitemid 40562792)
6. Ueffing N, Singh KK, Christians A, Thorns C, Feller AC, Nagl F et al. A single nucleotide polymorphism determines protein isoform production of the human c-FLIP protein. Blood 2009; 114: 572-579.
7. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10: 26-35. (Pubitemid 36511830)
8. Boatright KM, Renatus M, Scott FL, Sperandio S, Shin H, Pedersen IM et al. A unified model for apical caspase activation. Mol Cell 2003; 11: 529-541. (Pubitemid 36293843)
9. Chang DW, Xing Z, Capacio VL, Peter ME, Yang X. Interdimer processing mechanism of procaspase-8 activation. EMBO J 2003; 22: 4132-4142. (Pubitemid 37021742)
10. Donepudi M, Mac Sweeney A, Briand C, Grutter MG. Insights into the regulatory mechanism for caspase-8 activation. Mol Cell 2003; 11: 543-549. (Pubitemid 36297058)
11. Ueffing N, Keil E, Freund C, Kuhne R, Schulze-Osthoff K, Schmitz I. Mutational analyses of c-FLIPR, the only murine short FLIP isoform, reveal requirements for DISC recruitment. Cell Death Differ 2008; 15: 773-782. (Pubitemid 351405082)
12. Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signalling complex. J Biol Chem 2001; 276: 20633-20640.
13. Budd RC, Yeh WC, Tschopp J. cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol 2006; 6: 196-204. (Pubitemid 43290989)
14. Chang DW, Xing Z, Pan Y, Algeciras-Schimnich A, Barnhart BC, Yaish-Ohad S et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 2002; 21: 3704-3714. (Pubitemid 34787044)
15. Micheau O, Thome M, Schneider P, Holler N, Tschopp J, Nicholson DW et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 2002; 277: 45162-45171. (Pubitemid 36159119)
16. Fricker N, Beaudouin J, Richter P, Eils R, Krammer PH, Lavrik IN. Model-based dissection of CD95 signaling dynamics reveals both a pro-and antiapoptotic role of c-FLIPL. J Cell Biol 2010; 190: 377-389.
17. Dutton A, O'Neil JD, Milner AE, Reynolds GM, Starczynski J, Crocker J et al. Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc Natl Acad Sci USA 2004; 101: 6611-6616. (Pubitemid 38586022)
18. Mathas S, Lietz A, Anagnostopoulos I, Hummel F, Wiesner B, Janz M et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004; 199: 1041-1052. (Pubitemid 38619901)
19. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol 1998; 161: 2833-2840. (Pubitemid 28425704)
20. Medema JP, de Jong J, van Hall T, Melief CJ, Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med 1999; 190: 1033-1038. (Pubitemid 29480832)
21. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med 1999; 190: 1025-1032.
22. Wajant H, Gerspach J, Pfizenmaier K. Engineering death receptor ligands for cancer therapy. Cancer Lett 2011; e-pub ahead of print 13 January 2011; doi:10.1016/j.canlet.2010.12.019.
23. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163. (Pubitemid 29068521)
24. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682. (Pubitemid 26091143)
25. Voelkel-Johnson C. TRAIL-mediated signaling in prostate, bladder and renal cancer. Nat Rev Urol 2011; 8: 417-427.
26. O'Kane HF, Watson CJ, Johnston SR, Petak I, Watson RW, Williamson KE. Targeting death receptors in bladder, prostate and renal cancer. J Urol 2006; 175: 432-438. (Pubitemid 43067319)
27. Rosevear HM, Lightfoot AJ, O'Donnell MA, Griffith TS. The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guerin (BCG) immunotherapy for urothelial carcinoma of the bladder. Cancer Metastasis Rev 2009; 28: 345-353.
28. Korkolopoulou P, Goudopoulou A, Voutsinas G, Thomas-Tsagli E, Kapralos P, Patsouris E et al. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology 2004; 63: 1198-1204. (Pubitemid 38746841)
29. Steele LP, Georgopoulos NT, Southgate J, Selby PJ, Trejdosiewicz LK. Differential susceptibility to TRAIL of normal versus malignant human urothelial cells. Cell Death Differ 2006; 13: 1564-1576. (Pubitemid 44210359)
30. Schmitz I, Weyd H, Krueger A, Baumann S, Fas SC, Krammer PH et al. Resistance of short term activated T cells to CD95-mediated apoptosis correlates with de novo protein synthesis of c-FLIPshort. J Immunol 2004; 172: 2194-2200. (Pubitemid 38182366)
31. Fulda S, Meyer E, Debatin KM. Metabolic inhibitors sensitise for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Cancer Res 2000; 60: 3947-3956. (Pubitemid 32204591)
32. Krueger A, Baumann S, Krammer PH, Kirchhoff S. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001; 21: 8247-8254. (Pubitemid 33108586)
33. Ueffing N, Schuster M, Keil E, Schulze-Osthoff K, Schmitz I. Up-regulation of c-FLIP short by NFAT contributes to apoptosis resistance of short-term activated T cells. Blood 2008; 112: 690-698.
34. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 2004; 23: 3175-3185. (Pubitemid 39093611)
35. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C et al. CD95 promotes tumour growth. Nature 2010; 465: 492-496.
36. Legembre P, Barnhart BC, Peter ME. The relevance of NF-kappaB for CD95 signaling in tumor cells. Cell Cycle 2004; 3: 1235-1239. (Pubitemid 40268600)
37. Kreuz S, Siegmund D, Rumpf JJ, Samel D, Leverkus M, Janssen O et al. NFkappaB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP. J Cell Biol 2004; 166: 369-380. (Pubitemid 39031240)
38. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M et al. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 2011; 43: 449-463.
39. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 2011; 43: 432-448.
40. Swiatkowski S, Seifert HH, Steinhoff C, Prior A, Thievessen I, Schliess F et al. Activities of MAP-kinase pathways in normal uroepithelial cells and urothelial carcinoma cell lines. Exp Cell Res 2003; 282: 48-57. (Pubitemid 36062611)